Educational content on VJDementia is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ARUK 2023 | TREM2-targeted antibodies enhance microglial function in Alzheimer’s disease model

Elina Svensson, PhD Candidate, University College London Queen Square Institute of Neurology, London, UK, shares the findings of her research into TREM2-targeted antibodies as a therapeutic strategy in Alzheimer’s disease (AD). Microglia are known to play an important role in the development and progression of AD, with genome wide association studies showing that the majority of risk genes are highly, or even selectively, expressed by microglia. One such gene is TREM2, where the most common variant (R47H) is associated with a 2-4x increased risk of disease. Using human iPSC-derived microglia, antibody mediated TREM2 stimulation was shown to reduce TREM2 shedding, activate TREM2-dependent phospho-Syk signaling, and increase phagocytosis of amyloid-beta oligomers. This interview took place at the Alzheimer’s Research UK (ARUK) Conference 2023 in Aberdeen, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.